Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice

Molecular and Cellular Endocrinology

Volumn 348, Issue 1, 2012, Pages 104-111

  Lakshmanan, Arun Prasath ^a   Thandavarayan, Rajarajan A ^a   Watanabe, Kenichi ^a   Sari, Flori R ^a   Meilei, Harima ^a   Giridharan, Vijayasree V ^a   Sukumaran, Vijayakumar ^a   Soetikno, Vivian ^a   Arumugam, Somasundaram ^a   Suzuki, Kenji ^b   Kodama, Makoto ^b  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

AT 1R MAPK pathway; Diabetic nephropathy; Olmesartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN[1-7]; COLLAGEN TYPE 3; ENDOTHELIN 1; FIBRONECTIN; GLYCOPROTEIN GP 91; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; OLMESARTAN; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOPTOSIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; ENZYME ACTIVATION; GENE EXPRESSION; IMIDAZOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDYL-DIPEPTIDASE A; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, G-PROTEIN-COUPLED; TETRAZOLES;

EID: 80755172244     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.07.041     Document Type: Article

References (50)

1. Arozal W., Watanabe K., Veeraveedu P.T., Ma M., Thandavarayan R.A., Suzuki K., Tachikawa H., Kodama M., Aizawa Y. Effects of angiotensin receptor blocker on oxidative stress and cardio-renal function in streptozotocin-induced diabetic rats. Biol. Pharm. Bull. 2009, 32:1411-1416.
2. Awazu M., Ishikura K., Hida M., Hoshiya M. Mechanisms of mitogen-activated protein kinase activation in experimental diabetes. J. Am. Soc. Nephrol. 1999, 10:738-745.
3. Braam B., Mitchell K.D., Fox J., Navar L.G. Proximal tubular secretion of angiotensin II in rats. Am. J. Physiol. 1993, 264:F891-F898.
4. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., Remuzzi G., Snapinn S.M., Zhang Z., Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001, 345:861-869.
5. Burns K.D. Angiotensin II and its receptors in the diabetic kidney. Am. J. Kidney Dis. 2000, 36:449-467.
6. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R., Breitbart R.E., Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 2000, 87:E1-E9.
7. Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev. 2002, 23:599-622.
8. Ferrario C.M. Does angiotensin-(1-7) contribute to cardiac adaptation and preservation of endothelial function in heart failure?. Circulation 2002, 105:1523-1535.
9. Ferreira A.J., Santos R.A., Bradford C.N., Mecca A.P., Sumners C., Katovich M.J., Raizada M.K. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension 2010, 55:207-213.
10. Fliser D., Wagner K.K., Loos A., Tsikas D., Haller H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J. Am. Soc. Nephrol. 2005, 16:1135-1140.
11. Fujita H., Omori S., Ishikura K., Hida M., Awazu M. ERK and p38 mediate high-glucose-induced hypertrophy and TGF-beta expression in renal tubular cells. Am. J. Physiol. Renal. Physiol. 2004, 286:F120-F126.
12. Gava E., Samad-Zadeh A., Zimpelmann J., Bahramifarid N., Kitten G.T., Santos R.A., Touyz R.M., Burns K.D. Angiotensin-(1-7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells. Nephrol. Dial. Transplant. 2009, 24:1766-1773.
13. Geilen C.C., Wieprecht M., Orfanos C.E. The mitogen-activated protein kinases system (MAP kinase cascade): its role in skin signal transduction. J. Dermatol. Sci. 1996, 12:255-262.
14. Giani J.F., Muñoz M.C., Mayer M.A., Veiras L.C., Arranz C., Taira C.A., Turyn D., Toblli J.E., Dominici F.P. Angiotensin-(1-7) improves cardiac remodeling and inhibits growth-promoting pathways in the heart of fructose-fed rats. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H1003-H1013.
15. Gill P.S., Wilcox C.S. NADPH oxidases in the kidney. Antioxid. Redox. Signal. 2006, 8:1597-1607.
16. Gorin Y., Ricono J.M., Wagner B., Kim N.H., Bhandari B., Choudhury G.G., Abboud H.E. Angiotensin II-induced ERK1/ERK2 activation and protein synthesis are redox-dependent in glomerular mesangial cells. Biochem. J. 2004, 381:231-239.
17. Haneda M., Araki S., Togawa M., Sugimoto T., Isono M., Kikkawa R. Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 1997, 46:847-853.
18. Ingelfinger J.R. Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes. N. Engl. J. Med. 2011, 364:970-971.
19. Iordanov M., Bender K., Ade T., Schmid W., Sachsenmaier C., Engel K., Gaestel M., Rahmsdorf H.J., Herrlich P. CREB is activated by UVC through a p38/HOG-1-dependent protein kinase. EMBO J. 1997, 16:1009-1022.
20. Kiribayashi K., Masaki T., Naito T., Ogawa T., Ito T., Yorioka N., Kohno N. Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK. Kidney Int. 2005, 67:1126-1135.
21. Kyriakis J.M., Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 2001, 81:807-869.
22. Lakshmanan A.P., Watanabe K., Thandavarayan R.A., Sari F.R., Harima M., Giridharan V.V., Soetikno V., Kodama M., Aizawa Y. Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-γ agonist action. Free Radic. Res. 2011, 45:575-584.
23. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Ritz E., Atkins R.C., Rohde R., Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001, 345:851-860. Collaborative Study Group.
24. Li N., Zimpelmann J., Cheng K., Wilkins J.A., Burns K.D. The role of angiotensin converting enzyme 2 in the generation of angiotensin 1-7 by rat proximal tubules. Am. J. Physiol. Renal. Physiol. 2005, 288:F353-F362.
25. Long D.A., Price K.L., Herrera-Acosta J., Johnson R.J. How does angiotensin II cause renal injury?. Hypertension 2004, 43:722-723.
26. Moon, J.Y., Tanimoto, M., Gohda, T., Hagiwara, S., Yamazaki, T., Ohara, I., Murakoshi, M., Aoki, T., Ishikawa, Y., Lee, S.H., Jeong, K.H., Lee, T.W., Ihm, C.G., Lim, S.J., Tomino, Y., 2011. Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-Ay/Ta mice. Am. J. Physiol. Renal. Physiol. [Epub ahead of print].
27. Ogawa S., Mori T., Nako K., Kato T., Takeuchi K., Ito S. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 2006, 47:699-705.
28. Parving H.H., Lehnert H., Bröchner-Mortensen J., Gomis R., Andersen S., Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001, 345:870-878. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.
29. Pendergrass K.D., Averill D.B., Ferrario C.M., Diz D.I., Chappell M.C. Differential expression of nuclear AT1 receptors and angiotensin II within the kidney of the male congenic mRen2 Lewis rat. Am. J. Physiol. Renal. Physiol. 2006, 290:F1497-1506.
30. Pugsley M.K. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes. Proc. West. Pharmacol. Soc. 2005, 48:35-38.
31. Robinson M.J., Cobb M.H. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 1997, 9:180-186.
32. Roks A.J., Van Geel P.P., Pinto Y.M., Buikema H., Henning R.H., de Zeeuw D., van Gilst W.H. Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension 1999, 34:296-301.
33. Santos R.A., Simoes e Silva A.C., Maric C., Silva D.M., Machado R.P., de Buhr I., Heringer-Walther S., Pinheiro S.V., Lopes M.T., Bader M., Mendes E.P., Lemos V.S., Campagnole-Santos M.J., Schultheiss H.P., Speth R., Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. USA 2003, 100:8258-8263.
34. Sasso F.C., Carbonara O., Persico M., Iafusco D., Salvatore T., D'Ambrosio R., Torella R., Cozzolino D. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study. Diabetes Care 2002, 25:1909-1913.
35. Seikaly M.G., Arant B.S., Seney F.D. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J. Clin. Invest. 1990, 86:1352-1357.
36. Smith R.D., Yokoyama H., Averill D.B., Schiffrin E.L., Ferrario C.M. Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors. J. Am. Soc. Hypertens. 2008, 2:165-172.
37. Sonkodi S., Mogyorósi A. Treatment of diabetic nephropathy with angiotensin II blockers. Nephrol. Dial. Transplant. 2003, 18:21-23.
38. Su Z., Zimpelmann J., Burns K.D. Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int. 2006, 69:2212-2218.
39. Thandavarayan R.A., Watanabe K., Ma M., Gurusamy N., Veeraveedu P.T., Konishi T., Zhang S., Muslin A.J., Kodama M., Aizawa Y. Dominant-negative p38alpha mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H911-H919.
40. Thandavarayan R.A., Watanabe K., Sari F.R., Ma M., Lakshmanan A.P., Giridharan V.V., Gurusamy N., Nishida H., Konishi T., Zhang S., Muslin A.J., Kodama M., Aizawa Y. Modulation of doxorubicin-induced cardiac dysfunction in dominant-negative p38αmitogen-activated protein kinase mice. Free Radic. Biol. Med. 2010, 49:1422-1431.
41. Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., Turner A.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 2000, 275:33238-33243.
42. Tsiani E., Lekas P., Fantus I.G., Dlugosz J., Whiteside C. High glucose-enhanced activation of mesangial cell p38 MAPK by ET-1, ANG II, and platelet-derived growth factor. Am. J. Physiol. Endocrinol. Metab. 2002, 282:E161-E169.
43. Turner N.A., Ball S.G., Balmforth A.J. The mechanism of angiotensin II-induced extracellular signal-regulated kinase-1/2 activation is independent of angiotensin AT(1A) receptor internalization. Cell. Signal. 2001, 13:269-277.
44. Uchiyama-Tanaka Y., Matsubara H., Nozawa Y., Murasawa S., Mori Y., Kosaki A., Maruyama K., Masaki H., Shibasaki Y., Fujiyama S., Nose A., Iba O., Hasagawa T., Tateishi E., Higashiyama S., Iwasaka T. Angiotensin II signaling and HB-EGF shedding via metalloproteinase in glomerular mesangial cells. Kidney Int. 2001, 60:2153-2163.
45. Viberti G., Wheeldon N.M. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002, 106:672-678. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators.
46. Wang X.S., Diener K., Manthey C.L., Wang S., Rosenzweig B., Bray J., Delaney J., Cole C.N., Chan-Hui P.Y., Mantlo N., Lichenstein H.S., Zukowski M., Yao Z. Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. J. Biol. Chem. 1997, 272:23668-23674.
47. Westermann D., Rutschow S., Van Linthout S., Linderer A., Bücker-Gärtner C., Sobirey M., Riad A., Pauschinger M., Schultheiss H.P., Tschöpe C. Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia 2006, 49:2507-2513.
48. Wilmer W.A., Tan L.C., Dickerson J.A., Danne M., Rovin B.H. Interleukin-1beta induction of mitogen-activated protein kinases in human mesangial cells. Role of oxidation. J. Biol. Chem. 1997, 272:10877-10881.
49. Yano Y., Hoshide S., Ishikawa J., Noguchi C., Tukui D., Takanori H., Tada M., Kanemaru Y., Yano A., Ishikawa S., Shimada K., Kario K. The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients. Am. J. Hypertens. 2007, 20:565-572.
50. Zhu Z., Zhong J., Zhu S., Liu D., Van Der Giet M., Tepel M. Angiotensin-(1-7) inhibits angiotensin II-induced signal transduction. J. Cardiovasc. Pharmacol. 2002, 40:693-700.